Oct 21, 2025 | Press Releases
Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania–(Newsfile Corp. – October 21, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Sep 23, 2025 | Press Releases
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania–(Newsfile Corp. – September 23, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Sep 18, 2025 | Press Releases
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania–(Newsfile Corp. – September 18, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage...
Sep 3, 2025 | Press Releases
Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in on-going clinical studyKing of Prussia, Pennsylvania–(Newsfile Corp. – September 3, 2025) – Phio...
Aug 14, 2025 | Press Releases
Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania–(Newsfile Corp. – August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...
